TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21924563

Group type: COMPARATOR
Intervention: Brief advice by the practitioner
Number of subjects: 3086

Group type: EXPERIMENTAL
Intervention: Individually tailored computer‐generated letters
Number of subjects: 3086

Group type: EXPERIMENTAL
Intervention: Combination of both interventions
Number of subjects: 3086

Group type: EXPERIMENTAL
Intervention: Tailored letters
Number of subjects: 3086
Study: 20644019

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 6560
Study: 18271227

Group type: EXPERIMENTAL
Intervention: Chinese drugs acupoint injection (Danshen Injection and Chaihu Injection)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Saline acupoint injection
Number of subjects: 150

Group type: COMPARATOR
Intervention: Huichun Ruyi capsules
Number of subjects: 150
Study: 16302325

Group type: EXPERIMENTAL
Intervention: 1% clindamycin/zinc gel applied once daily
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: 1% clindamycin/zinc gel applied twice daily
Number of subjects: 246

Group type: COMPARATOR
Intervention: 1% clindamycin lotion applied twice daily
Number of subjects: 246
Study: 12044272

Group type: EXPERIMENTAL
Intervention: VAQTA, TyphimVi, and YF‐VAX on day 0 and VAQTA at week 24 (Group 1)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: TyphimVi and YF‐VAX on day 0 and an optional dose of VAQTA 1 month later (Group 2)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: VAQTA at day 0 and week 24 (Group 3)
Number of subjects: 240
Study: 9860240

Group type: EXPERIMENTAL
Intervention: Low-pseudoallergen diet for 3 weeks followed by provocation with food rich in pseudoallergens
Number of subjects: 16

Group type: COMPARATOR
Intervention: Double-blind, placebo-controlled food challenges
Number of subjects: 16
Study: 7617493

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2508161

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg orally administered diazepam
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 202346

Group type: EXPERIMENTAL
Intervention: Clozapine 25 mg/night for three consecutive nights
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31699704

Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 IU/day)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: n-3 FA (1 g/day)
Number of subjects: 784

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 784
Study: 29976582

Group type: EXPERIMENTAL
Intervention: Alteplase treatment decision based on NIHSS scores
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Conjoint model analysis
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Model accounting for all possible interactions
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Factors influencing treatment decisions
Number of subjects: 156
Study: 27351218

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Bevacizumab + Tie2 + Ca125
Number of subjects: 92
Study: 24757227

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 16
Study: 22892110

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 mg twice a day for 5 consecutive days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo 100 mg twice a day for 5 consecutive days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20706917

Group type: EXPERIMENTAL
Intervention: Panic Control Treatment for Adolescents (PCT‐A)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Self‐monitoring control group
Number of subjects: 26
Study: 17954368

Group type: EXPERIMENTAL
Intervention: Quinapril alone for 1 week
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Amlodipine alone for 6 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Quinapril + Amlodipine for 6 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Amlodipine alone after discontinuation of Quinapril for 6 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Muscle sympathetic nerve activity (MSNA)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Angiotensin II levels
Number of subjects: 21
Study: 16135167

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (352 mg per day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bromhexine hydrochloride (4 mg per day)
Number of subjects: 30
Study: 12371046

Group type: EXPERIMENTAL
Intervention: Phone calls and mailings once every month for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: No intervention phone calls or mailings (control group)
Number of subjects: 50
Study: 10466282

Group type: EXPERIMENTAL
Intervention: Intrapartum practices that are demonstrably safe and useful
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intrapartum practices with trade-offs between beneficial and adverse effects
Number of subjects: 0
Study: 7475592

Group type: EXPERIMENTAL
Intervention: Joint consultation sessions of GPs and orthopaedic surgeons (n = 144)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Usual-care control group (n = 128)
Number of subjects: 272
Study: 2248816

Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 7016484

Group type: EXPERIMENTAL
Intervention: Neomycin plus magnesium sulfate
Number of subjects: 173

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 173
Study: 30641129

Group type: EXPERIMENTAL
Intervention: Septal myectomy with subvalvular intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Septal myectomy without subvalvular intervention
Number of subjects: 80
Study: 27808528

Group type: EXPERIMENTAL
Intervention: Avoidant coping style
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Diabetes-related distress
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Self-management behaviors
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Glycemic control (hemoglobin A1c)
Number of subjects: 264
Study: 26718674

Group type: EXPERIMENTAL
Intervention: Substrate-based ablation
Number of subjects: 118

Group type: COMPARATOR
Intervention: Clinical VT ablation
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Combined incidence of rehospitalization and mortality
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Periprocedural complications
Number of subjects: 118
Study: 23278355

Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol (breath alcohol concentration 50 mg/dl)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 32
Study: 21933534

Group type: EXPERIMENTAL
Intervention: Vaccinated group
Number of subjects: 14883
Study: 19156155

Group type: EXPERIMENTAL
Intervention: MLCT
Number of subjects: 112

Group type: COMPARATOR
Intervention: LCT
Number of subjects: 112
Study: 17158146

Group type: EXPERIMENTAL
Intervention: Behavioural strategies delivered over individual structured MCH consultations
Number of subjects: 328

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 328
Study: 14992558

Group type: EXPERIMENTAL
Intervention: Oats-containing gluten-free diet (50 g daily)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Traditional gluten-free diet (without oats)
Number of subjects: 39
Study: 10584476

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg/day for 5 days, tapered progressively)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 9097714

Group type: EXPERIMENTAL
Intervention: FSGS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MCD
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 30
Study: 1827040

Group type: EXPERIMENTAL
Intervention: Collagen-impregnated prosthesis
Number of subjects: 123

Group type: COMPARATOR
Intervention: Non-impregnated Dacron prosthesis
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Collagen-impregnated prosthesis (aneurysmal disease)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Non-impregnated Dacron prosthesis (aneurysmal disease)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Collagen-impregnated prosthesis (occlusive disease)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Non-impregnated Dacron prosthesis (occlusive disease)
Number of subjects: 123
Study: 6949237

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 51

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 51
Study: 31318392

Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab combination therapy (1500 mg durvalumab every 4 weeks and 75 mg tremelimumab every 4 weeks for 4 cycles, followed by durvalumab monotherapy for up to 12 months)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Durvalumab monotherapy (1500 mg every 4 weeks for up to 12 months)
Number of subjects: 65
Study: 29334436

Group type: EXPERIMENTAL
Intervention: 0.454% stabilized stannous fluoride dentifrice (Crest® Pro‐Health™)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 0.30% triclosan dentifrice (Colgate® Total®)
Number of subjects: 200
Study: 24999214

Group type: EXPERIMENTAL
Intervention: 4% cocaine (n = 39)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 6% cocaine (n = 40)
Number of subjects: 79
Study: 22684565

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 20693265

Group type: EXPERIMENTAL
Intervention: Early-stage memory loss support group (ESML)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 142
Study: 17545007

Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No induction therapy
Number of subjects: 0
Study: 15716702

Group type: EXPERIMENTAL
Intervention: 20 mg/day enalapril (ACE inhibitor)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 12059936

Group type: EXPERIMENTAL
Intervention: NIT/gutta-percha
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: NIT without gutta-percha
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (lateral condensation, McSpadden technique)
Number of subjects: 66
Study: 10530414

Group type: EXPERIMENTAL
Intervention: Roquinimex (Linomide), 0.2 mg/kg body weight, twice weekly for 2 years
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8543206

Group type: EXPERIMENTAL
Intervention: diclofenac-sodium 0.1% eye drops
Number of subjects: 41

Group type: COMPARATOR
Intervention: placebo (vehicle)
Number of subjects: 41
Study: 2031798

Group type: EXPERIMENTAL
Intervention: Sodium diatrizoate (ionic monomer) at 150 mg I/ml (726 mosmol/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iopamidol (non-ionic monomer) diluted to the same iodine concentration but at 324.3 mosmol/kg
Number of subjects: 0
Study: 6138593

Group type: EXPERIMENTAL
Intervention: RA 27/3
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cendehill
Number of subjects: 100
Study: 30919942

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 83985

Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 83985
Study: 29161417

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU oral weekly for 12 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (oral weekly for 12 weeks)
Number of subjects: 41
Study: 26879279

Group type: EXPERIMENTAL
Intervention: AMG 334 70 mg
Number of subjects: 483

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: AMG 334 7 mg
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: AMG 334 21 mg
Number of subjects: 483
Study: 24854605

Group type: EXPERIMENTAL
Intervention: CARE kV (automated attenuation-based tube potential optimization mode)
Number of subjects: 89

Group type: COMPARATOR
Intervention: 120 kV
Number of subjects: 89
Study: 22339125

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r) 600/100 mg bid
Number of subjects: 595

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) 400/100 mg bid
Number of subjects: 595
Study: 20540443

Group type: EXPERIMENTAL
Intervention: Diazepam (5-40 mg) and Flumazenil (0.36 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (during the placebo phase)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.36 mg)
Number of subjects: 6
Study: 17454203

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17560289

Group type: EXPERIMENTAL
Intervention: Enoxaparin (ENOX)
Number of subjects: 20479

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 20479
Study: 14977992

Group type: EXPERIMENTAL
Intervention: Mycobacterial purified protein derivatives (PPDs)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (UK subjects)
Number of subjects: 2
Study: 10623956

Group type: EXPERIMENTAL
Intervention: Exercise program (3 times a week for 12 weeks) targeting muscle force, endurance, balance, and flexibility
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 45
Study: 9366455

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (bupivacaine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anesthesia (isoflurane and nitrous oxide)
Number of subjects: 40
Study: 1483797

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg slow release every 8 hours)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 17
Study: 6364778

Group type: EXPERIMENTAL
Intervention: Multiagent chemotherapy including cyclophosphamide, imidazolecarboxamide, and vincristine given in 5-day pulses each month for 12 courses.
Number of subjects: 133

Group type: COMPARATOR
Intervention: Multiagent chemotherapy (as prescribed).
Number of subjects: 133

Group type: COMPARATOR
Intervention: Previous treatment regimen from study CCG 011 (no chemotherapy or oral CPM).
Number of subjects: 133
Study: 30935469

Group type: EXPERIMENTAL
Intervention: Selective dorsal neurectomy (SDN) in group 2a
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (group 2b)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Comparison of dorsal penile nerve branches
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 142
Study: 29961772

Group type: EXPERIMENTAL
Intervention: EUS-Guided Biliary Drainage (EUS-BD)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Endoscopic Retrograde Cholangiopancreatography (ERCP)
Number of subjects: 125
Study: 27802843

Group type: EXPERIMENTAL
Intervention: Weight Action Programme (WAP)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Nurse intervention (best usual care)
Number of subjects: 330
Study: 24807502

Group type: EXPERIMENTAL
Intervention: Internet healthcare education and symptom flares consultation through short message service
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 80
Study: 22683137

Group type: EXPERIMENTAL
Intervention: Exenatide twice daily
Number of subjects: 1029

Group type: COMPARATOR
Intervention: Glimepiride once daily
Number of subjects: 1029
Study: 19055510

Group type: EXPERIMENTAL
Intervention: Queckenstedt's test (Q-test)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham test
Number of subjects: 39
Study: 18063177

Group type: EXPERIMENTAL
Intervention: Low tunnel position (2 o'clock)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High tunnel position (1 o'clock)
Number of subjects: 60
Study: 15841092

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus (3 x 10^10 CFU, two capsules, three times a day for 6 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (two capsules, three times a day for 6 weeks)
Number of subjects: 80
Study: 12469331

Group type: EXPERIMENTAL
Intervention: 400 mg albendazole
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 800 mg albendazole
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1200 mg albendazole
Number of subjects: 10
Study: 9585394

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 1305

Group type: COMPARATOR
Intervention: Chlorpropamide
Number of subjects: 1305

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose > or = 10.0 mmol/l
Number of subjects: 1305

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose > or = 7.8 mmol/l to < 10.0 mmol/l
Number of subjects: 1305

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose < 7.8 mmol/l
Number of subjects: 1305

Group type: EXPERIMENTAL
Intervention: Non-obese subjects (BMI < 30 kg/m²)
Number of subjects: 1305

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI > or = 30 kg/m²)
Number of subjects: 1305

Group type: EXPERIMENTAL
Intervention: Lower beta-cell function
Number of subjects: 1305
Study: 7805822

Group type: EXPERIMENTAL
Intervention: Waterloo Smoking Prevention Program 1, adapted
Number of subjects: 792

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 792
Study: 2817307

Group type: EXPERIMENTAL
Intervention: Turbuhaler (terbutaline inhalation)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nebuhaler (terbutaline inhalation)
Number of subjects: 21
Study: 51664

Group type: EXPERIMENTAL
Intervention: Heparinoid cream
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31492999

Group type: EXPERIMENTAL
Intervention: Hydroxycinnamic acid amides (HCAA) profiling using mass spectrometry-multiple reaction monitoring (UPLC-MRM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxycinnamic acid esters (HCAE) profiling using ultra-performance liquid chromatography-photodiode array detection (UPLC-PDA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial least square discriminant analysis (PLS-DA) applied to both HCAE and HCAA datasets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of supplement samples
Number of subjects: 0
Study: 27879193

Group type: EXPERIMENTAL
Intervention: Flumagen® 370 mg tablet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Somalgen® 370 mg tablet
Number of subjects: 0
Study: 25597371

Group type: EXPERIMENTAL
Intervention: gatifloxacin 0.3%
Number of subjects: 40

Group type: COMPARATOR
Intervention: moxifloxacin 0.5%
Number of subjects: 40
Study: 25389489

Group type: EXPERIMENTAL
Intervention: Oral education program
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Video education program
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (pre-intervention)
Number of subjects: 90
Study: 22675288

Group type: EXPERIMENTAL
Intervention: Glycemic Index (GI) change
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Glycemic Load (GL) change
Number of subjects: 756
Study: 19683152

Group type: EXPERIMENTAL
Intervention: Biaxial microincision cataract surgery with UltraChoice 1.0 Rollable Thinlens intraocular lens (IOL)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Biaxial microincision cataract surgery with UltraChoice 1.0 Rollable Thinlens IOL
Number of subjects: 150
Study: 17575467

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg/day) + Pioglitazone (30 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Losartan (100 mg/day)
Number of subjects: 60
Study: 15236135

Group type: EXPERIMENTAL
Intervention: Pneumatic cuff technique
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Valsalva maneuver
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combined application of Valsalva maneuver and pneumatic cuff techniques
Number of subjects: 81
Study: 12660264

Group type: EXPERIMENTAL
Intervention: FSH (1200 IU)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: hCG (5000 IU)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (stimulation test 1)
Number of subjects: 25
Study: 10589951

Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CsA
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study: 8961475

Group type: EXPERIMENTAL
Intervention: Dexamethasone (20 mg) in addition to ondansetron (8 mg three times a day)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo in addition to ondansetron (8 mg three times a day)
Number of subjects: 104
Study: 1742515

Group type: EXPERIMENTAL
Intervention: nizatidine 150 mg
Number of subjects: 108

Group type: COMPARATOR
Intervention: ranitidine 150 mg
Number of subjects: 108
Study: 7342331

Group type: EXPERIMENTAL
Intervention: Praziquantel 25 mg per kg body weight bid for one day (Group III)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Praziquantel 25 mg per kg body weight in a single dose (Group IV)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Praziquantel 40 mg per kg body weight in a single dose (Group V)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Mild and transient side effects (all groups)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Clinical improvement (all groups)
Number of subjects: 97
Study: 30623548

Group type: EXPERIMENTAL
Intervention: 8-week comprehensive exercise training
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study: 28877108

Group type: EXPERIMENTAL
Intervention: Heel protector
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard care (pillows)
Number of subjects: 54
Study: 26761398

Group type: EXPERIMENTAL
Intervention: Cognitive therapy sessions analysis
Number of subjects: 35
Study: 25086427

Group type: EXPERIMENTAL
Intervention: Self-control feedback (KR feedback for half of their trials whenever they wanted)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Instructor-control feedback (KR feedback after half of both their good and bad trials)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no feedback for any trials)
Number of subjects: 22
Study: 22630801

Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) therapy (12 sessions of computer-assisted CR)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) therapy
Number of subjects: 41
Study: 19649678

Group type: EXPERIMENTAL
Intervention: Risk index based on 39 risk factors including age, gender, BMI, perceived health, and various health conditions.
Number of subjects: 24115
Study: 17848424

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/day)
Number of subjects: 4000